Verition Fund Management
HRTX icon

Verition Fund Management’s Heron Therapeutics HRTX Stock Holding History

Verition Fund Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-102,843
Closed -$157K – 3486
2024
Q4 		$157K Sell
102,843
-5,272
-5% -$8.54K ﹤0.01% 3024
2024
Q3 		$215K Buy
108,115
+83,542
+340% +$199K ﹤0.01% 2845
2024
Q2 		$86K Buy
+24,573
New +$75.5K ﹤0.01% 2745
2020
Q1 		– Sell
-10,626
Closed -$250K – 811
2019
Q4 		$250K Buy
+10,626
New +$235K ﹤0.01% 884
2018
Q4 		– Sell
-6,581
Closed -$208K – 1017
2018
Q3 		$208K Buy
+6,581
New +$245K 0.01% 1161

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verition Fund Management's HRTX Position: Q1 2025 in Review

Verition Fund Management sold out of Heron Therapeutics (HRTX) in Q1 2025, closing a stake of 102,843 shares — an estimated $157K sold.

Verition Fund Management first reported a position in HRTX in Q3 2018 and held it in 5 quarters. The position peaked at $250K in Q4 2019. 164 funds tracked by Wall St. Rank hold HRTX as of Q1 2025.

  • Verition Fund Management reported no remaining Heron Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 102,843 Heron Therapeutics shares in Q1 2025, an estimated $157K.
  • Verition Fund Management first reported a position in Heron Therapeutics in Q3 2018 and held it in 5 quarters.
  • Verition Fund Management's Heron Therapeutics position peaked at $250K in Q4 2019.
  • 164 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.